Hematology Frontier

In the vast river of life, blood flows like an unceasing stream, nourishing every inch of land and supporting the vitality and vigor of every life. Anemia, a seemingly inconspicuous…

In today’s information overload era, how can one stay updated on the latest advancements in the field? Here, we curate the most recent literature each month, focusing on hot topics and offering a comprehensive analysis of the latest developments in hematologic diseases. Join us as we track the latest trends, gain insights into scientific research, and explore the limitless possibilities in the world of hematology. Stay tuned—don’t miss our monthly updates!

Marginal zone lymphoma (MZL), a group of indolent mature B-cell lymphomas, presents a significant challenge in treatment selection due to its high heterogeneity. Despite improvements in survival rates for MZL patients with the advent of new drugs and advancements in clinical diagnostic and therapeutic techniques, developing a balanced management plan that addresses both efficacy and safety across a long disease course and lifetime management remains an urgent issue. At the recent "8th Academic Conference on Hematologic Oncology" organized by the Chinese Society of Clinical Oncology (CSCO), Dr. Huilai Zhang from Tianjin Medical University Cancer Institute & Hospital delivered a compelling presentation titled "Current Status and Treatment Progress for Chinese Patients with Marginal Zone Lymphoma." This report offers valuable insights and forward-looking guidance for comprehensively understanding the current state of MZL diagnosis and treatment in China and mastering the latest developments in the field. This article summarizes the key points of Professor Zhang's presentation for our readers.

To further enhance the diagnostic and treatment techniques for leukemia and lymphoma in China, the 8th Hematology Oncology Academic Conference was held from July 26 to 28 in Harbin. This event was jointly organized by the Chinese Society of Clinical Oncology (CSCO), the CSCO Leukemia Expert Committee, and the Lymphoma Expert Committee, and co-hosted by the Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital. The conference aimed to provide a significant platform for in-depth learning and extensive exchange among experts and scholars in the field of hematologic oncology. On this occasion, Hematology Frontier had the privilege of inviting Dr. Qian Jiang from Peking University People's Hospital to share her insights on the treatment models and unmet needs for newly diagnosed chronic myeloid leukemia (CML) patients.

Hemophilia, a rare congenital bleeding disorder, is caused by pathogenic variants in the encoding genes, leading to the complete or partial deficiency of clotting factors VIII (Hemophilia A) or IX (Hemophilia B). Treating hemophilia involves certain complexities, and until now, no evidence-based clinical practice guidelines based on the GRADE methodology have been established to guide treatment. The International Society on Thrombosis and Haemostasis (ISTH) has developed evidence-based clinical practice guidelines aimed at systematically reviewing the relevant evidence to provide a scientific basis for treatment decisions in Hemophilia A and B, thereby supporting healthcare providers in their clinical practice. To this end, ISTH formed a globally representative, multidisciplinary guideline panel that prioritized clinical questions based on their urgency and the importance of outcomes to patients and clinicians.

The warm summer in Harbin was matched by a surge of medical wisdom. The 8th Hematology  Academic Conference of the Chinese Society of Clinical Oncology (CSCO), hosted by the Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was held from July 26 to 28, 2024, in Harbin. This grand event brought together many top experts and scholars from both domestic and international fields, showcasing the latest research results and clinical experiences in the treatment of hematologic malignancies. Hematology Frontier had the privilege of inviting Dr. Tiejun Gong from the Harbin Institute of Hematology and Oncology to share his unique insights and experiences from this conference, highlight the key expert guidelines, and discuss the standout content of the Northeast Hematologic Oncology Standardized Diagnosis and Treatment session.

Marginal zone lymphoma (MZL), a group of indolent mature B-cell lymphomas, presents a significant challenge in treatment selection due to its high heterogeneity. Despite improvements in survival rates for MZL patients with the advent of new drugs and advancements in clinical diagnostic and therapeutic techniques, developing a balanced management plan that addresses both efficacy and safety across a long disease course and lifetime management remains an urgent issue. At the recent "8th Academic Conference on Hematologic Oncology" organized by the Chinese Society of Clinical Oncology (CSCO), Dr. Huilai Zhang from Tianjin Medical University Cancer Institute & Hospital delivered a compelling presentation titled "Current Status and Treatment Progress for Chinese Patients with Marginal Zone Lymphoma." This report offers valuable insights and forward-looking guidance for comprehensively understanding the current state of MZL diagnosis and treatment in China and mastering the latest developments in the field. This article summarizes the key points of Professor Zhang's presentation for our readers.

Marginal zone lymphoma (MZL), a group of indolent mature B-cell lymphomas, presents a significant challenge in treatment selection due to its high heterogeneity. Despite improvements in survival rates for MZL patients with the advent of new drugs and advancements in clinical diagnostic and therapeutic techniques, developing a balanced management plan that addresses both efficacy and safety across a long disease course and lifetime management remains an urgent issue. At the recent "8th Academic Conference on Hematologic Oncology" organized by the Chinese Society of Clinical Oncology (CSCO), Dr. Huilai Zhang from Tianjin Medical University Cancer Institute & Hospital delivered a compelling presentation titled "Current Status and Treatment Progress for Chinese Patients with Marginal Zone Lymphoma." This report offers valuable insights and forward-looking guidance for comprehensively understanding the current state of MZL diagnosis and treatment in China and mastering the latest developments in the field. This article summarizes the key points of Professor Zhang's presentation for our readers.

In January 2023, a review by Professor Tao Cheng  from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College was published in the international academic journal ——Blood Science . The title of the study is "Spatially resolved transcriptomics: advances and applications". This review summarizes the interplay between technological innovation and biological discovery continues to push the boundaries of what was previously imaginable, translating our approach to complex biological systems and disease pathology.

Recently, the Blood Transfusion Department at The First Hospital of Handan in Hebei Province identified an extremely rare B subtype blood type. This blood type results from a heterozygous mutation in exon 7 of the ABO allele, specifically c.449A>G, making it even rarer than the well-known "Panda Blood" (Rh-negative blood).